Scientific

Posters & Presentations

Posters & Presentations

November 5, 2022 | ASN A Regimen of Nonmyeloablative Conditioning and CD8+/TCR- Facilitating Cells Tips the Balance Towards Immune Down-Regulation and Away from Cytopathic Activity in Kidney Allograft Recipients

November 5, 2022 | ASN Immune Cell Transcriptome in Living-Donor Kidney Transplant Patients Tolerized with Allo-HSCT Cell Therapy

June 7, 2022 | ATC The Promise of Tolerance in Living Donor Kidney Transplant (LDKT): A Retrospective, Real-World Assessment of the Safety and Efficacy of LDKT with FCR001 Investigational Cell-Therapy Compared with Standard of Care (SOC)

June 7, 2022 | ATC Fcγ Receptor-Positive Cells Play a Critical Role in Rejection of Allogeneic Bone Marrow Cells Mediated by Anti-Donor Antibodies

June 7, 2022 | ATC Experience With COVID-19 Infection and Vaccination in Combined Kidney/HSCT Recipients

June 7, 2022 | ATC Long-Term Follow-Up of a Phase 2 Clinical Trial to Induce Tolerance in Living Donor Kidney Transplant Recipients

June 7, 2022 | ATC Identification of a Unique and Mechanistic Urinary Cell mRNA Signature in Tolerant Kidney Transplant Recipients Conditioned with FCR001 Facilitating Cells

Dec. 14, 2021 | ASH Establishment of durable chimerism with minimal graft versus host disease in highly mismatched recipients receiving an investigational facilitated allo-HSCT

Nov. 4, 2021 | ASN Preserved Kidney Allograft Function and Unique Urinary Biomarker Profiles in Living Donor Kidney Transplant (LDKT) Patients Tolerized with an Investigational Allo-HSCT Cell Therapy

June 4, 2021 | ATC  Long-Term Follow-Up of a Phase 2 Clinical Trial to Induce Tolerance in Living Donor Renal Transplant Recipients

 

 


If you are a health care provider and would like to receive more information about our clinical trials, please email medicalinformation@talaristx.com

If you are a patient and would like to receive more information about our clinical trials, please email patientinformation@talaristx.com